INSIGHTS ON SOLID DOSE MANUFACTURING

• Orally-Disintegrating Dosage Forms With Taste Masked Multiparticulates

  Learn more about our orally disintegrating tablet (ODT) capabilities and how these innovative technologies have the potential to improve acceptance, adherence, and compliance in pharmacotherapy.

• Combining Patient Centricity And Commercial Viability In Pediatric Product Development

  Medication acceptance and adherence are critical concerns in pediatric populations due to these patients’ rapid anatomical and physiological development.

• Taste-Masked Dosage Forms For Pediatric Oral Delivery: An Industrial Perspective

  Leveraging strategies and technologies for pediatric patient compliance for taste masking and controlled release in pharmaceutical products, enables flexibility in dosage and format options.

• Developing And Manufacturing Drugs With HPAPIs

  Learn why companies must invest in specialized expertise to develop scalable, safe, and efficient manufacturing processes for highly potent oral solid dose products.

• Navigating High-Potency OSD Manufacturing

  4/13/2026

  Learn how containment strategy, process design, and early risk‑based decisions influence operator protection, compliance, and long‑term manufacturing success as potency levels continue to rise.

• How To Solve Complex Pediatric Dosing Challenges Using Tailored Solutions

  8/11/2025

  With a partner who understands the science, the regulations, and the real-world demands of dosing children, development can move faster, smarter, and with greater confidence

• Accelerating An Innovative High Potency Oncology Therapy To Market

  5/13/2026

  Learn how disciplined containment, proactive risk management, and collaboration accelerate complex oncology programs under tight timelines while protecting quality, safety, and global launch readiness.

• Modern Containment Solutions In OSD Processes

  6/15/2026

  Outdated containment infrastructure in OSD facilities creates costly compliance gaps and operational bottlenecks. Flexible single-use isolator systems offer a faster, more adaptable path forward.

• Closing The Duration Gap In FDA-Approved Long-Acting Contraceptives

  7/17/2024

  A gap exists between three months and three years in FDA-approved long-acting contraceptives (LACs). A microsphere formulation enables sustained release over a six to twelve-month period.